Skip to main content

Table 2 Selected published results of SRS (2000–2015) for the treatment of GH-secreting pituitary adenomas

From: Target delineation and optimal radiosurgical dose for pituitary tumors

Authors

Patients

Type

Dose

Follow-up

Tumor

Biochemical

Late toxicity (%)

of SRS

(Gy)

(months)

control (%)

remission (%)

visual

hypopituitarism

Zhang et al., 2000 [84]

68

GK

31a

34

100

40

NA

NA

Izawa et al., 2000 [85]

29

GK

22.5a

26.4

93

41

0

0

Attanasio et al., 2003 [86]

30

GK

20a

46

100

23

0

6.3

Jane et al., 2003 [87]

64

GK

15a

> 18

100

36

0

28

Castinetti et al., 2005 [88]

82

GK

28.5a

49.5

100

17

1.2

16

Gutt et al., 2005 [89]

44

GK

23a

23

100

48

0

NA

Kobayashi et al., 2005 [90]

67

GK

18.9a

63.3

100

17

11.1

14.6

Jezkova et al., 2006 [91]

96

GK

35a

53.7

100

50 (44 at 5 years)

0

27.1

Voges et al., 2006 [66]

64

LINAC

16.5

54.3

97

37.5 (33 at 5 years)

1,4

12.3 (18 at 5 years)

Petit et al., 2007 [92]

22

Protons

20

75

95

59

0

38

Pollock et al., 2007 [93]

46

GK

20a

63

100

50 (60 at 5 years)

2.2

36

Roberts et al., 2007 [82]

9

CK

18–24a

25.4

100

44.4

0

33

Vik-Mo et al., 2007 [94]

61

GK

26.5a

66

100

38 (58 at 5 years)

0

23

Jagannathan et al., 2008 [95]

95

GK

22a

57

98

53

4.2

34

Losa et al., 2008 [96]

83

GK

21.5a

69

97.6

60 (52 at 5 years)

0

8.5 (11.8 at 5 years)

Ronchi et al., 2009 [97]

35

GK

20a

114

100

82 (46 at 10 years)

0

50

Wan et al., 2009 [98]

103

GK

21.4a

67.3

95.1

36.9

NA

1.7

Hayashi et al., 2010 [70]

25

GK

25a

36

100

40

0

0

Iwai et al., 2010 [99]

26

GK

20a

84

96

38 (17 at 5 years)

0

8

Castinetti et al., 2009 [100]

43

GK

26a

96

100

42,0

0

23

Poon et al., 2010 [101]

40

GK

29a

73.8

NA

17

0

11.4

Erdur et al., 2011 [102]

22

GK

23.8a

60

95,2

54,5

0

28.6

Sheehan et al., 2011 [36]

130

GK

24a

31

93

53

2.3

34

Sicignano et al., 2012 [37]

39

GK

25a

60

97.7

54

NA

12.3

Franzin et al., 2012 [103]

103

GK

22.5a

71

97,3

60.7 (57 at 5 years)

0

7.8

Liu et al., 2012 [104]

40

GK

21a

72

97,5

47,5

0

40

Zeiler et al., 2013 [105]

21

GK

14.2a

33

100

30

3.9

13.2

Yan et al., 2013 [106]

22

LINAC

23

98

95

68.2

0

22.7

Wilson et al., 2013 [107]

86

LINAC

20

66

96

18.6

1,2

19.8

Lee et al., 2014 [108]

136

GK

25a

61.5

98.5

65.4 (73.4 at 6 years)

3.7

31.6

Wattson et al., 2014 [109]

50

Protons

20

51.5

100

48 (49 at 5 years)

0

57 (62 at 5 years)

Bostrom et al., 2015 [110]

21

LINAC

20

96

97.1

23

5

46.4

  1. SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed
  2. amarginal dose; ^1–3 fractions